High risk non-muscle invasive bladder cancer (NMIBC) is a recurring and potentially lethal disease. To date, with the exception of radical surgery, there are no validated strategies for patients not responding to intravesical BCG therapy. Immune Checkpoint Inhibitors (ICI) are currently being tested for BCG-resistant NMIBC. We report current available data and ongoing trials exploring the efficacy and safety of ICI in this setting.
Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era / Albisinni, Simone; Martinez Chanza, Nieves; Aoun, Fouad; Diamand, Romain; Mjaess, Georges; Azzo, Jean-Michel; Esperto, Francesco; Bellmunt, Joaquim; Roumeguère, Thierry; DE Nunzio, Cosimo. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6442. - (2021). [10.23736/S2724-6051.21.04309-5]
Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era
Albisinni, Simone;Esperto, Francesco;DE Nunzio, Cosimo
2021
Abstract
High risk non-muscle invasive bladder cancer (NMIBC) is a recurring and potentially lethal disease. To date, with the exception of radical surgery, there are no validated strategies for patients not responding to intravesical BCG therapy. Immune Checkpoint Inhibitors (ICI) are currently being tested for BCG-resistant NMIBC. We report current available data and ongoing trials exploring the efficacy and safety of ICI in this setting.| File | Dimensione | Formato | |
|---|---|---|---|
|
Albisinni_Immune-checkpoint_2021.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
687.67 kB
Formato
Adobe PDF
|
687.67 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
